Get the Stockscreener App
4.72
8.70%
-0.45
After Hours:
4.72
Lyra Therapeutics Inc stock is currently priced at $4.72, with a 24-hour trading volume of 157.13K.
It has seen a -8.70% decreased in the last 24 hours and a -23.00% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $5.19 pivot point. If it approaches the $4.96 support level, significant changes may occur.
Previous Close:
$5.17
Open:
$5.16
24h Volume:
157.13K
Market Cap:
$281.99M
Revenue:
$1.56M
Net Income/Loss:
$-62.68M
P/E Ratio:
-3.0256
EPS:
-1.56
Net Cash Flow:
$-64.35M
1W Performance:
-9.06%
1M Performance:
-23.00%
6M Performance:
+42.60%
1Y Performance:
+100.00%
1D Range:
$4.7001
$5.20
52W Range:
$2.26
$6.79
Lyra Therapeutics Inc Stock (LYRA) Company Profile
Name
Lyra Therapeutics Inc
Sector
Industry
Phone
617 393 4600
Address
480 Arsenal Way, Watertown, MA
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-31-23 | Initiated | H.C. Wainwright | Buy |
| May-24-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-26-20 | Initiated | BTIG Research | Buy |
| May-26-20 | Initiated | BofA/Merrill | Buy |
| May-26-20 | Initiated | Jefferies | Buy |
| May-26-20 | Initiated | William Blair | Outperform |
View All
Lyra Therapeutics Inc Stock (LYRA) Latest News
Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock?
Zacks Investment Research
Lyra Therapeutics (LYRA) Is a Great Choice for 'Trend' Investors, Here's Why
Zacks Investment Research
Wall Street Analysts See a 101.81% Upside in Lyra Therapeutics (LYRA): Can the Stock Really Move This High?
Zacks Investment Research
Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Lyra Therapeutics Inc Stock (LYRA) Financials Data
Lyra Therapeutics Inc (LYRA) Revenue 2024
LYRA reported a revenue (TTM) of $1.56 million for the quarter ending December 31, 2023, a +14.31% rise year-over-year.
Lyra Therapeutics Inc (LYRA) Net Income 2024
LYRA net income (TTM) was -$62.68 million for the quarter ending December 31, 2023, a -13.39% decrease year-over-year.
Lyra Therapeutics Inc (LYRA) Cash Flow 2024
LYRA recorded a free cash flow (TTM) of -$64.35 million for the quarter ending December 31, 2023, a -47.77% decrease year-over-year.
Lyra Therapeutics Inc (LYRA) Earnings per Share 2024
LYRA earnings per share (TTM) was -$1.29 for the quarter ending December 31, 2023, a +38.57% growth year-over-year.
Lyra Therapeutics Inc Stock (LYRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | Director |
May 31 '23 |
Buy |
2.49 |
3,610,832 |
8,999,999 |
11,469,117 |
| ANDERSON EDWARD T | Director |
May 31 '23 |
Buy |
2.43 |
1,805,416 |
4,387,161 |
2,521,745 |
| NBVM GP, LLC | 10% Owner |
May 31 '23 |
Buy |
2.43 |
1,805,416 |
4,387,161 |
2,521,745 |
About Lyra Therapeutics Inc
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
1.53%
3.38%
Cap:
|
Volume (24h):